Posted by Michael Wonder on 13 Aug 2024
Government, Lilly Korea turn a blind eye to Retevmo’s prohibitive cost
12 August 2024 - Patients are appealing to the government to cover the cost of Lilly Korea's Retevmo (selpercatinib), the only RET inhibitor in Korea.
On Monday last week, a petition was posted on an online billboard for public consent, calling for the uncovered drug to get benefits from national health insurance.
